161 related articles for article (PubMed ID: 25732707)
21. Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin.
Gupta V; Su YS; Wang W; Kardosh A; Liebes LF; Hofman FM; Schönthal AH; Chen TC
Neurosurg Focus; 2006 Apr; 20(4):E20. PubMed ID: 16709026
[TBL] [Abstract][Full Text] [Related]
22. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
Kim JT; Kim JS; Ko KW; Kong DS; Kang CM; Kim MH; Son MJ; Song HS; Shin HJ; Lee DS; Eoh W; Nam DH
Oncol Rep; 2006 Jul; 16(1):33-9. PubMed ID: 16786120
[TBL] [Abstract][Full Text] [Related]
23. Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24).
Heffeter P; Jakupec MA; Körner W; Wild S; von Keyserlingk NG; Elbling L; Zorbas H; Korynevska A; Knasmüller S; Sutterlüty H; Micksche M; Keppler BK; Berger W
Biochem Pharmacol; 2006 Feb; 71(4):426-40. PubMed ID: 16343446
[TBL] [Abstract][Full Text] [Related]
24. Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model.
Ouyang M; White EE; Ren H; Guo Q; Zhang I; Gao H; Yanyan S; Chen X; Weng Y; Da Fonseca A; Shah S; Manuel ER; Zhang L; Vonderfecht SL; Alizadeh D; Berlin JM; Badie B
PLoS One; 2016; 11(2):e0148139. PubMed ID: 26829221
[TBL] [Abstract][Full Text] [Related]
25. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
26. Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme.
Veeravagu A; Liu Z; Niu G; Chen K; Jia B; Cai W; Jin C; Hsu AR; Connolly AJ; Tse V; Wang F; Chen X
Clin Cancer Res; 2008 Nov; 14(22):7330-9. PubMed ID: 19010848
[TBL] [Abstract][Full Text] [Related]
27. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
[TBL] [Abstract][Full Text] [Related]
28. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Recinos VR; Tyler BM; Bekelis K; Sunshine SB; Vellimana A; Li KW; Brem H
Neurosurgery; 2010 Mar; 66(3):530-7; discussion 537. PubMed ID: 20173548
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
30. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
Pollack IF; Erff M; Ashkenazi A
Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
[TBL] [Abstract][Full Text] [Related]
31. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
Geoerger B; Gaspar N; Opolon P; Morizet J; Devanz P; Lecluse Y; Valent A; Lacroix L; Grill J; Vassal G
Int J Cancer; 2008 Jul; 123(1):209-16. PubMed ID: 18386816
[TBL] [Abstract][Full Text] [Related]
32. [The sodium pump could constitute a new target to combat glioblastomas].
Lefranc F; Mijatovic T; Kiss R
Bull Cancer; 2008 Mar; 95(3):271-81. PubMed ID: 18390407
[TBL] [Abstract][Full Text] [Related]
33. The antitumor effects of Angelica sinensis on malignant brain tumors in vitro and in vivo.
Tsai NM; Lin SZ; Lee CC; Chen SP; Su HC; Chang WL; Harn HJ
Clin Cancer Res; 2005 May; 11(9):3475-84. PubMed ID: 15867250
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.
Kanzawa T; Bedwell J; Kondo Y; Kondo S; Germano IM
J Neurosurg; 2003 Dec; 99(6):1047-52. PubMed ID: 14705733
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of Src enhances the cytotoxic effect of temozolomide through AKT in glioma.
Wang Z; Sun J; Li X; Yang S; Yue S; Zhang J; Yang X; Zhu T; Jiang R; Yang W
Oncol Rep; 2013 Apr; 29(4):1395-8. PubMed ID: 23338526
[TBL] [Abstract][Full Text] [Related]
36. GSK1838705A, an IGF-1R inhibitor, inhibits glioma cell proliferation and suppresses tumor growth in vivo.
Zhou X; Shen F; Ma P; Hui H; Pei S; Chen M; Wang Z; Zhou W; Jin B
Mol Med Rep; 2015 Oct; 12(4):5641-6. PubMed ID: 26238593
[TBL] [Abstract][Full Text] [Related]
37. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles.
Lam FC; Morton SW; Wyckoff J; Vu Han TL; Hwang MK; Maffa A; Balkanska-Sinclair E; Yaffe MB; Floyd SR; Hammond PT
Nat Commun; 2018 May; 9(1):1991. PubMed ID: 29777137
[TBL] [Abstract][Full Text] [Related]
38. PPARgamma and RXRgamma ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models.
Papi A; Tatenhorst L; Terwel D; Hermes M; Kummer MP; Orlandi M; Heneka MT
J Neurochem; 2009 Jun; 109(6):1779-90. PubMed ID: 19457135
[TBL] [Abstract][Full Text] [Related]
39. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
Saito R; Bringas JR; Panner A; Tamas M; Pieper RO; Berger MS; Bankiewicz KS
Cancer Res; 2004 Oct; 64(19):6858-62. PubMed ID: 15466173
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of CKD-602, a camptothecin derivative, in a mouse glioma model.
Kim CY; Lee SJ; Kim SK; Park CK; Wang KC; Cho BK
J Clin Neurosci; 2012 Feb; 19(2):301-5. PubMed ID: 22154203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
